Biostock writes about Elicera and CAR T-cells

April 15, 2021

CAR T-cell therapies have shown transformational potential for the treatment liquid tumours. The recent approval of Bristol Myers Squibb’ multiple myeloma CAR T drug Abecma brings the number of CAR T therapy approvals up to five, with three coming during the last year alone. However, despite the remarkable innovation and excitement surrounding this technology, major challenges still remain, especially with regard to solid tumour treatments. Swedish gene therapy company Elicera may have what it takes to get past these hurdles.

Download attachment (pdf)
< Back to press releases